ClinicalTrials.gg
Active, not recruitingNCT05820087#HOPE4KIDNEYUpdated Jun 23, 2026

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

An interventional study of HistoSonics Edison System in Renal Cancer, Tumor, Solid and Kidney Cancer, sponsored by HistoSonics, Inc.. Active, not recruiting at 15 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by HistoSonics, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 551 studies in Kidney Neoplasms with a site in United States — 65 open to participants now, 109 under way, 4 of them phase 3. Kidney Neoplasms · United States.

Enrollment
137th of 443
67 · median 37
Started
2024
with 12 others
No phase
58 of 551
10 open now
Primary completion
2025-09
later than 16 of 103 live
Registered
493rd of 551
by date

Among the 551 studies in Kidney Neoplasms with a site in United States, this one is the 137th largest by enrollment of the 443 interventional ones that give a count, is one of 13 that started in 2024, is one of 58 with no phase, reaches primary completion later than 16 of the 103 other live ones, and was the 493rd registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 208 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

65 of the 551 studies in Kidney Neoplasms with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 171 Kidney Neoplasms studies recruiting now, 131 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 551 studies in Kidney Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.

Read the detailed description

This trial is a prospective, multi-center, single-arm pivotal trial designed to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors. Data through 90 days for all enrolled subjects will be summarized in a primary analysis to be submitted for Regulatory Submission to the FDA. Additionally, subjects will be followed for five (5) years post-index procedure, with evaluations at the 14-day, 30-day, 90-day, 180-day and annual time points.

03

Conditions studied

  • Renal Cancer
  • Tumor, Solid
  • Kidney Cancer
  • Tumor
  • Tumor, Benign
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥22 years of age.
  2. Subject has signed the Institutional Review Board (IRB) approved trial Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
  3. Subject is diagnosed with only one (1) non- solid renal mass ≤3cm confirmed via CT or MRI ≤30 days prior to the index procedure date.
  4. Subject has had a to determine the type of tumor, ≥14 days prior to the index procedure.
  5. Subject can tolerate general anesthesia.
  6. Subject has an Performance Status (ECOG PS) grade 0-2 at baseline screening.
  7. Subject meets all the following functional criteria at ≤14 days prior to the planned index procedure date:

    • White Blood Count (WBC) ≥3,000/mm3 (≥3 10*9/L)
    • (ANC) ≥1,200/mm3 (≥1.2 10*9/L)
    • (Hgb) ≥9 g/dL
    • count ≥100,000/mm3 (≥100 10*9/L)
  8. Subject has an (Glomerular filtration rate) ≥45mL/min, ≤14 days prior to the planned index procedure date.
  9. The tumor selected for histotripsy treatment must be ≤3cm in longest diameter.
  10. Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics Edison System.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period.
  2. Subject is being actively treated in another pharmaceutical or device trial ≤30 days prior to planned index procedure date that may interfere with the primary endpoint(s).
  3. Subjects who have active cancers (not in remission for the last two years) other than non-melanomatous skin cancers.
  4. In the Investigator's opinion, the subject has co-morbid disease(s) or condition(s) that would cause undue risk and preclude safe use of the HistoSonics Edison System.
  5. Subject is on dialysis, being considered for dialysis or has acute renal failure.
  6. Subject has not recovered to (CTCAE) grade 2 or better from any adverse effects (except alopecia and neuropathy) related to previous therapy.
  7. Subject has an (INR) >1.5 or uncorrectable coagulopathy, (e.g., known von Willebrand disease, hemophilia, or on anticoagulants), on the planned index procedure date.
  8. Subject is taking Aspirin (ASA) or NSAIDS ≤7 days prior to the planned index procedure date.
  9. Subject has a less than one (\< 1) year.
  10. In the investigator's opinion, histotripsy is not a treatment option for the subject.
  11. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
  12. Subject's targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, radiation).
  13. Subject's targeted tumor is not treatable by the HistoSonics Edison System's working ranges (refer to User Guide).
  14. In the investigator's opinion, the anticipated risks of intervention outweigh the potential benefits of the intervention.
  15. Subject has bilateral kidney tumors or has a single functioning kidney.
  16. Subject has a genetic predisposition to kidney cancer such as:

    • Von Hippel Lindau (VHL)
    • Hereditary Papillary Renal Carcinoma (HPRC)
    • Birt-Hogg-Dubé Syndrome (BHD)
    • Tuberous Sclerosis Complex (TSC)
    • Hereditary Leiomyomata's Renal Cell Carcinoma (HLRCC)
    • Reed's Syndrome
    • Succinate Dehydrogenase B Deficiency (SDHB)
    • BRCA 1 associated protein -1 (BAP1) Renal Cell Carcinoma
    • MITF predisposed Renal Cell Carcinoma
  17. The targeted tumor is an angiomyolipoma.
  18. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
  19. Subject has a urinary tract infection (UTI) ≤7 days prior to the planned index procedure date.
  20. The targeted tumor is not clearly visible with ultrasound, MRI or CT.
  21. Targeted tumor with adequate margin overlaps the renal pelvis, main renal vessel, ureter, organ or other vital structure.
  22. The treatment of the tumor will not allow an adequate margin (as determined by the investigator).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    HistoSonics Edison System

    Device: HistoSonics Edison System

Interventions

  • DeviceHistoSonics Edison System

    Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.

    Also known as: Histotripsy

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint - Primary technique efficacy defined as the percentage of targeted tumors that were successfully eliminated after a single histotripsy session as assessed by contrast enhanced MRI or CT at 90 days.

    Primary Effectiveness Endpoint

    Time frame: 90 days Post Index Procedure

  2. Primary Safety Endpoint - Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 30 days after the histotripsy procedure.

    Primary Safety Endpoint

    Time frame: 30 days Post Index Procedure

Secondary outcomes

  1. Secondary Effectiveness Endpoint- Technical success demonstrating complete coverage of the targeted tumor as determined post-index procedure (≤36 hours) by contrast enhanced MRI or CT in subjects whom treatment was initiated.

    Secondary Effectiveness Endpoint - Technical success defined as completion of histotripsy treatment according to protocol and demonstrating complete coverage of the targeted tumor as determined post-index procedure (≤36 hours) by contrast enhanced MRI or CT in subjects whom treatment was initiated.

    Time frame: Up to 36 hours Post Index Procedure

  2. Secondary Safety Endpoint - Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 90 days after the histotripsy procedure.

    Secondary Safety Endpoint

    Time frame: 90 days Post Index Procedure

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Sep 2025, 20 months.

Of 97 interventional studies with no phase under Kidney Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 90. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2023
First posted
Apr 19, 2023
StartActual
Jan 4, 2024
Primary completionActual
Sep 4, 2025
CompletionEst.
Jul 2030
Results delay requested
Jun 18, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05820087
Lead sponsor
HistoSonics, Inc.
Responsible party
Sponsor
First posted
Apr 19, 2023
Start date
Jan 4, 2024
Primary completion
Sep 4, 2025
Completion
Jul 2030 (estimated)
Last update
Jun 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion